The Three Pillars of PMOS: A Deep Dive Into the Science Behind the Name
Polyendocrine. Metabolic. Ovarian. Each word is a pillar. Each pillar holds up the next.
Polyendocrine. Metabolic. Ovarian. Each word is a pillar. Each pillar holds up the next. Understanding the architecture changes everything about how we treat, how we prevent, and how we save lives.
By Dr. Herman Weiss, MD, MBA, FACOG | The Metabolic Fix | May 2026
In my last post, I wrote about why the renaming of PCOS to PMOS — Polyendocrine Metabolic Ovarian Syndrome — is one of the most consequential reframings in women’s health in a generation.
Today I want to go deeper. Much deeper.
Because if you only understand that the name changed, you’ve missed the most important part. The name is not three random adjectives strung together. Those three words — Polyendocrine. Metabolic. Ovarian. — are three pillars of a biological architecture that has been collapsing on women for decades while we argued about the wallpaper.
Each pillar is distinct. Each has its own mechanisms, its own clinical consequences, its own opportunities for intervention. But here is what nobody teaches in medical school, what almost no patient is ever told, and what the old name made nearly impossible to communicate:
The three pillars don’t stand independently. They collapse into each other.
Understand the cascade, and you understand the disease. Understand the disease, and you can actually fix it.
Let’s build this from the ground up.
Pillar One: Polyendocrine — The Fire That Started Everything
The Hypothalamus Doesn’t Know It’s Misfiring
Every story about PMOS begins in the brain. Not in the ovaries. Not in the bloodstream. In the hypothalamus — specifically, in a small population of neurons called KNDy neurons (kisspeptin, neurokinin B, dynorphin) housed in the arcuate nucleus, deep in the basal hypothalamus.
These neurons are the GnRH pulse generator. Their job is to fire in a precise, rhythmic pattern — sending kisspeptin signals that drive the gonadotropin-releasing hormone (GnRH) neurons to release their pulses into the portal circulation. Those GnRH pulses travel to the anterior pituitary and orchestrate the exquisitely timed release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Timing is everything. A slow GnRH pulse frequency favors FSH secretion — the hormone that nurtures follicles, drives estrogen production, and enables ovulation. A fast GnRH pulse frequency favors LH secretion — the hormone that triggers ovulation and, in excess, drives androgen production from the ovarian theca cells.
In PMOS, the pulse generator is stuck on fast.
A neuroendocrine hallmark of the syndrome is persistently rapid GnRH pulsatility, which favors pituitary synthesis of LH over FSH and contributes to the increased LH concentrations and LH:FSH ratios that are typical of this disorder.
The result is a pituitary that is chronically over-producing LH and under-producing FSH. And that ratio imbalance — more LH, less FSH — is the opening move in a pathophysiological chess game that plays out across years and decades in the body of nearly every woman with PMOS.
Why Is the Pulse Generator Misfiring?
This is where PMOS gets fascinating — and where the architecture of the disease reveals itself as genuinely polygenic and multi-system.
Meta-analyses of large-scale genomic analyses and recent definitive studies confirm that PMOS has polygenic origins across neuroendocrine, metabolic, and reproductive pathways. This is not a single-gene disorder. It is a convergence of multiple biological vulnerabilities, amplified by each other.
Several inputs are now known to drive aberrant GnRH pulsatility:
Hyperandrogenism feeds back to the hypothalamus. Androgens — testosterone, androstenedione — act directly on GnRH neurons to increase their firing rate. This creates one of the most vicious feedback loops in all of endocrinology: faster GnRH pulses → more LH → more androgen production from theca cells → faster GnRH pulses. The system accelerates itself.
Anti-Müllerian Hormone (AMH) amplifies the loop. Serum AMH concentrations are elevated in women with PCOS, and a recent series of experiments provided compelling evidence that AMH can directly stimulate GnRH neuron activity and secretion. In women with PMOS, the accumulation of arrested small antral follicles produces excess AMH — and that excess AMH loops back to stimulate the same GnRH neurons that are already firing too fast. The disease amplifies its own neuroendocrine driver.
Insulin resistance completes the neuroendocrine triangle. An additional contributing factor to the hyperandrogenic state is hyperinsulinemia resulting from insulin resistance, which upregulates LH receptors and promotes androgen secretion at thecal cells. So the metabolic dysfunction — which we’ll explore in Pillar Two — doesn’t stay in the metabolic compartment. It reaches back up into the brain and makes the neuroendocrine dysregulation worse.
The Multi-Gland Problem
Here is why the word “polyendocrine” is doing real scientific work.
The HPO axis dysfunction described above would be enough to justify the prefix. But PMOS doesn’t stop at the hypothalamic-pituitary-ovarian axis. The adrenal glands are frequently co-involved — contributing their own excess androgens (DHEA-S, androstenedione) in what’s called adrenal hyperandrogenism, present in roughly 20-30% of women with PMOS. The pancreas is dysregulated — producing excess insulin in a futile attempt to overcome peripheral resistance. Adipose tissue is hormonally active — secreting adipokines that further dysregulate appetite, inflammation, and metabolic signaling. There are emerging signals about thyroid co-involvement and hypothalamic-pituitary-adrenal axis dysregulation under chronic stress.
This is not an ovarian problem. This is a multi-gland, multi-axis, neuroendocrine systems failure. The word “polyendocrine” doesn’t capture everything — it just captures the most important things.
What This Means Clinically
Understanding the polyendocrine pillar has direct, actionable implications for how we evaluate and treat:
A woman with PMOS who presents with irregular cycles, hair loss, acne, and anxiety is not presenting with a gynecological complaint. She is presenting with evidence of a neuroendocrine system that is dysregulated at the level of the hypothalamus, pituitary, adrenal glands, and ovaries simultaneously.
Measuring her androgens — total and free testosterone, DHEA-S, androstenedione — is not optional. Understanding her LH/FSH ratio is not optional. Considering her stress physiology, her cortisol pattern, her thyroid status is not optional. These are the clinical expressions of a polyendocrine system in distress.
And critically: the neuroendocrine dysregulation begins early. A recent study of daughters of women with PCOS, who are at high risk for developing PCOS, found that postmenarcheal adolescents exhibit high circulating LH and AMH concentrations, with a positive correlation between the two — compatible with a putative role of AMH in the neuroendocrine defects.
The fire started in the brain. In many women, it started in adolescence. And nobody told them.
Pillar Two: Metabolic — The Accelerant
The neuroendocrine dysregulation of Pillar One creates a hormonal environment that feeds directly into metabolic catastrophe. And then that metabolic catastrophe feeds back and makes the neuroendocrine dysregulation worse. This is the engine that drives PMOS from a hormonal disorder into a systemic, life-shortening disease.
Insulin Resistance: The Central Metabolic Defect
If hyperandrogenism is the signature of Pillar One, insulin resistance is the signature of Pillar Two — and it is arguably the most consequential feature of PMOS that the old name made invisible.
Insulin resistance and compensatory hyperinsulinaemia are present in 85% of affected individuals — including 75% of lean women with PMOS — amplifying androgen secretion and disrupting steroidogenesis, highlighting the metabolic-endocrine interplay.
Let that number sit with you. Seventy-five percent of lean women with PMOS have insulin resistance. Not overweight women. Lean women. Women whose doctors looked at them and said, “You look fine.” Women whose BMI was normal and who were sent home without metabolic evaluation because the name of their condition pointed toward their ovaries, not their pancreas.
The mechanism of insulin resistance in PMOS is unique and still not fully understood — but what is clear is that it is intrinsic to the disease, not secondary to weight gain. Women with PMOS have evidence of defects in the post-receptor insulin signaling pathway, specifically involving the PI3K/AKT/MAPK pathway, that are present regardless of adiposity. The ovaries, paradoxically, remain sensitive to insulin’s mitogenic and steroidogenic effects even when they are resistant to its metabolic effects — a selective resistance that drives hyperandrogenism directly.
The Hyperinsulinemia-Hyperandrogenism Loop
Here is where Pillars One and Two fully merge:
Excess insulin → direct stimulation of ovarian theca cells to produce more androgens → more androgens → faster GnRH pulsatility → more LH → more theca cell stimulation. The insulin resistance doesn’t just create metabolic disease. It turbocharges the androgen excess that was already driving the neuroendocrine dysregulation. This is not a complication of PMOS. This is the second engine of the disease itself.
At the same time, excess insulin suppresses the production of sex hormone-binding globulin (SHBG) in the liver — the protein that binds androgens and keeps them biologically inactive. As SHBG falls, free testosterone rises even if total testosterone is unchanged. This is why women with PMOS can have “normal” total testosterone levels and still experience severe androgen-driven symptoms. Free testosterone is what matters. And insulin — through SHBG suppression — is what frees it.
The Long Game: What Insulin Resistance Does to a Woman’s Life
The metabolic pillar is where PMOS stops being a condition of irregular periods and starts being a condition that determines whether a woman lives to see her grandchildren.
The likelihood of developing metabolic disorders is about three to seven times higher in women with PMOS than in women without it. Insulin resistance is common even in lean women with PMOS.
Diabetes onset was, on average, 10 years earlier among women with PCOS than in women without PCOS.
Ten years earlier. Read that again. A woman with PMOS who develops type 2 diabetes doesn’t develop it at 55. She develops it at 45 — at the peak of her career, when her children are teenagers, when she still believes she has decades of metabolic headroom. And because nobody screened her insulin at 25, nobody connected her irregular cycles to her insulin levels at 30, nobody explained the cascade she was already in — she had no opportunity to intervene.
The cardiovascular picture is equally sobering. Women with PMOS carry elevated levels of small, dense LDL particles — the atherogenic fraction — alongside reduced HDL and elevated triglycerides. Subclinical coronary atherosclerosis has been detected in adolescents with PMOS. Endothelial dysfunction is measurable early. And metabolic dysfunction leads to a risk for cardiovascular disease that increases with aging in women with PMOS — with the severity of insulin resistance associated with the amount of abdominal obesity, even in lean women.
The silent metabolic damage begins before the diagnosis is made. It continues during the years of diagnostic delay. It compounds through every year that the treatment plan focuses only on cycles and fertility rather than fasting insulin, lipids, liver function, and vascular health.
Non-Alcoholic Fatty Liver Disease: The Invisible Complication
NAFLD in PMOS is chronically underrecognized, underscreened, and underreported — and it is a direct metabolic consequence of the insulin resistance of Pillar Two.
Hyperinsulinemia drives hepatic de novo lipogenesis — the liver converts excess glucose into fat. Visceral adiposity, even in lean women with PMOS, generates a chronic flux of free fatty acids to the liver. The result is hepatic steatosis, which can progress to steatohepatitis (NASH), fibrosis, and cirrhosis. Women with PMOS have a dramatically elevated prevalence of NAFLD relative to age- and BMI-matched controls.
When was the last time a gynecologist ordered a hepatic function panel and an abdominal ultrasound on a 28-year-old with irregular cycles?
That is a rhetorical question. And its answer is an indictment.
Inflammation: The Thread Running Through Everything
Lean and obese patients with PCOS both have chronic inflammation mediating the long-term cardiometabolic complications and comorbidities observed — including dyslipidemia, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease.
Chronic low-grade inflammation is not a side effect of PMOS. It is woven into its pathophysiology. Elevated inflammatory cytokines — IL-6, TNF-α, CRP — are consistently measurable in women with PMOS regardless of BMI, and they participate directly in worsening insulin resistance, amplifying androgen production, and damaging the vascular endothelium. The gut microbiome — specifically the estrobolome, which we’ll address in a future piece — is a key regulator of this inflammatory state, and its dysbiosis in PMOS is increasingly well-documented.
Inflammation also explains the psychological burden. Women with PMOS have significantly elevated rates of anxiety and depression — not just as a psychological response to a chronic illness, but as a direct neurobiological consequence of the inflammatory cytokines and hormonal dysregulation that are remodeling their brain chemistry in real time.
What This Means Clinically
The metabolic evaluation of a woman with PMOS is not optional. It is not a nice-to-have. It is the clinical assessment that determines her 20-year trajectory.
Every woman with PMOS should receive at minimum: fasting insulin and glucose (and ideally a 2-hour oral glucose tolerance test), a full lipid panel with attention to triglycerides and HDL, hepatic function tests, high-sensitivity CRP, and serious conversation about cardiovascular risk beginning in her 20s.
This is what “metabolic medicine” looks like in practice. And it was nearly impossible to justify ordering when the name of the disease said “ovarian syndrome.”
PMOS makes it mandatory.
Pillar Three: Ovarian — The Consequence Made Visible
The neuroendocrine fire of Pillar One, accelerated by the metabolic dysfunction of Pillar Two, lands in the ovaries with full force. Pillar Three is where the damage becomes visible — in the follicles, in the cycles, in the fertility, and in the long-term gynecological health of women who go undiagnosed for years.
Folliculogenesis Arrest: When Development Stalls
Normal ovarian physiology depends on a precise sequence. Each month, a cohort of primordial follicles is recruited. Under FSH stimulation, one follicle emerges as dominant — growing from a 2mm antral follicle to a 20mm preovulatory follicle, producing rising estradiol, triggering the LH surge, and releasing a mature oocyte. The remaining follicles undergo atresia.
In PMOS, this sequence is disrupted at multiple points simultaneously.
Enhanced androgen production from ovarian theca cells occurs due to increased LH levels, and decreased FSH leads to folliculogenesis arrest, accumulating small antral follicles and ultimately increasing AMH levels.
The elevated LH stimulates theca cells to produce excess androgens. The deficient FSH fails to provide adequate granulosa cell stimulation for follicular maturation. Heightened luteinizing hormone, insulin resistance, and obesity stimulate theca cell androgen production, while granulosa cell dysfunction impairs aromatization of androgens to estrogens.
The result: follicles don’t die — they arrest. They stall at the small antral stage, accumulating in the ovarian cortex. The ovary fills with developmentally suspended follicles — the “polycystic” morphology that gave the old name its anatomical anchor. But here is the critical insight that the old name obscured: the cysts didn’t cause the disease. They are the footprint of it. The follicular arrest is the downstream consequence of the neuroendocrine and metabolic dysregulation that came first.
Many women with PMOS — including those with insulin resistance, hyperandrogenism, irregular cycles, and full metabolic risk profiles — never develop the characteristic ovarian morphology on ultrasound. The absence of “cysts” is not the absence of disease. It never was. The name just made everyone think it was.
AMH: The Ovarian Marker That Explains Everything
Anti-Müllerian hormone has emerged as one of the most illuminating biomarkers in PMOS — and its story elegantly closes the loop between all three pillars.
AMH is produced exclusively by the granulosa cells of small antral follicles. In a normal ovary with a normal follicular cohort, AMH levels reflect the ovarian reserve. In PMOS, with its accumulation of arrested small antral follicles, AMH levels are dramatically elevated — often two to three times higher than age-matched controls.
But AMH doesn’t just sit there as a passive marker. As we saw in Pillar One, elevated AMH loops back to the hypothalamus — directly stimulating GnRH neuron activity and contributing to the neuroendocrine dysregulation that initiated the cascade. The ovary, through its excess AMH production, becomes a participant in perpetuating its own dysfunction.
A 2023 retrospective cohort study found that serum AMH levels were significantly higher in women with insulin resistance, with positive correlations noted between AMH, insulin resistance measures, fasting insulin, androgens, and LH/FSH ratio — suggesting that elevated AMH may be linked to increased insulin resistance.
The ovary is not a victim in PMOS. It is an active contributor to the endocrine chaos. And its primary messenger — AMH — is the signal that ties everything together.
Anovulation and Its Consequences: Beyond Infertility
The folliculogenesis arrest of Pillar Three means that many women with PMOS ovulate infrequently or not at all — a state called oligoanovulation. The clinical expression is irregular or absent menstrual cycles. And while the immediate concern for most patients is fertility, the consequences of chronic anovulation extend far beyond reproductive capacity.
Progesterone deficiency. Every ovulation produces a corpus luteum. The corpus luteum produces progesterone. No ovulation means no corpus luteum means no progesterone in the luteal phase. Sustained progesterone deficiency, with unopposed estrogen, creates chronic endometrial proliferation — a direct pathway to endometrial hyperplasia and, without intervention, endometrial cancer. The endometrial cancer risk in women with PMOS is three to four times that of the general population. This is not a fertility concern. This is an oncological concern.
Bone density. Progesterone and estrogen both play roles in bone mineral density maintenance. Chronic anovulation — particularly in lean women with PMOS — creates a hormonal environment that impairs bone formation and increases fracture risk over time.
Pregnancy complications. For women with PMOS who do conceive — spontaneously or with assistance — the background metabolic and endocrine dysregulation increases the risks of gestational diabetes, pre-eclampsia, preterm birth, and large-for-gestational-age infants. The ovarian pillar doesn’t end when pregnancy begins.
The Androgen Signature on the Skin and Scalp
The androgen excess that is simultaneously a driver and a consequence of the three-pillar cascade expresses itself visibly in ways that are often dismissed, minimized, or attributed to stress or aging:
Hirsutism — terminal hair growth in androgen-sensitive areas. Acne — particularly jawline, neck, and back, in patterns different from adolescent acne. Androgenic alopecia — progressive temporal and crown hair loss that is devastating to self-image and is frequently misdiagnosed or untreated. Seborrhea. Acanthosis nigricans — the dark, velvety hyperpigmentation at the neck, armpits, and groin that is a visible marker of insulin resistance.
These are not cosmetic complaints. They are clinical signs of the full PMOS cascade, written on the surface of the body for any clinician who has been taught to read them.
What This Means Clinically
The ovarian evaluation of PMOS requires a fundamental reframe. Ultrasound is a useful tool — but it is neither necessary nor sufficient for diagnosis, and the presence or absence of polycystic ovarian morphology should never be the gating criterion for taking a woman’s symptoms seriously.
The ovarian pillar is best understood as a readout — an anatomical and functional expression of the neuroendocrine and metabolic dysfunction that preceded it. Treating the ovarian manifestations in isolation — inducing ovulation without addressing insulin resistance, prescribing the pill without addressing androgen excess mechanisms, managing irregular cycles without monitoring endometrial health — is treating the symptom while ignoring the fire.
The Architecture: How the Pillars Fall Into Each Other
This is the cascade that every clinician needs to understand — and every woman with PMOS deserves to be taught:
The hypothalamus fires too fast → GnRH pulses accelerate → LH rises, FSH falls. Elevated LH drives theca cells to overproduce androgens. Deficient FSH fails to support follicular maturation.
Excess androgens feed back to the hypothalamus → GnRH fires faster → the neuroendocrine loop tightens.
Insulin resistance develops (driven by intrinsic metabolic defects, amplified by the androgenic environment) → Hyperinsulinemia develops → Insulin directly stimulates theca cells to produce more androgen → SHBG falls → Free testosterone rises → More hyperandrogenism → Faster GnRH pulsatility.
Elevated AMH from arrested follicles loops back to hypothalamic GnRH neurons → Further accelerates the pulse frequency → Further raises LH → Further suppresses FSH → Further impairs follicular maturation → More follicular arrest → More AMH.
Chronic inflammation, generated by insulin resistance, visceral adiposity, and gut dysbiosis, amplifies every step of the cascade — worsening insulin resistance, worsening androgen production, damaging the endothelium, dysregulating appetite hormones, remodeling brain chemistry.
The ovary — saturated with excess LH, excess androgens, deficient FSH, excess insulin, and elevated AMH — arrests its follicles, fails to ovulate, fails to produce progesterone, and becomes a source of further androgenic and AMH-mediated amplification.
This is not a circle. It is a spiral. And without intervention — real, comprehensive, metabolically and endocrinologically informed intervention — it tightens with every passing year.
Why This Architecture Is a Clinical Opportunity
I don’t tell this story to frighten anyone. I tell it because understanding the cascade means understanding where to interrupt it.
The good news — and there is very good news — is that each pillar has addressable mechanisms. The neuroendocrine dysregulation can be modulated by approaches that reduce androgen excess and normalize GnRH pulsatility. The metabolic dysfunction responds to insulin sensitization — through nutritional intervention, targeted nutraceuticals (inositols, chromium, cinnamon, folate, zinc), lifestyle modification, and where appropriate, pharmaceutical support. The ovarian consequences improve when the upstream dysfunction is addressed — not through hormonal suppression alone, but through metabolic restoration that removes the androgenic drive from theca cells and restores FSH-mediated follicular maturation.
The three-pillar architecture of PMOS is not a counsel of despair. It is a map. And maps are what physicians use to navigate toward health.
The Naming Catches Up to the Science
Polyendocrine: recognizes that the condition is underpinned by multiple interacting hormonal disturbances, including insulin, androgens, and neuroendocrine hormones, rather than being an isolated ovarian disorder. Metabolic: acknowledges the inherent metabolic features such as insulin resistance, obesity, and increased risks for type 2 diabetes and cardiovascular disease. Ovarian: retains the connection to ovarian dysfunction, including ovulatory disturbances and infertility, which remain defining features of the syndrome.
One name. Three pillars. Decades of science finally compressed into five syllables that tell the truth about what is happening in 170 million women’s bodies worldwide.
This is why the name change matters. Not because names are magic. But because this name, for the first time, gives every clinician, every patient, every researcher, and every policymaker the same accurate map.
Now we have to use it.
Coming next: The Gut-Hormone Axis in PMOS — How the Estrobolome Connects Intestinal Bacteria to Androgen Excess, Insulin Resistance, and Folliculogenesis. The microbiome isn’t a side story. It may be the missing chapter.
Dr. Herman Weiss, MD, MBA, FACOG, is a board-certified OB/GYN with 25 years of clinical experience and the CEO/Founder of ProvationLife™, a physician-led women’s metabolic health company. Follow @hweissmd for daily clinical insights on women’s metabolic health.
Key Sources:
Teede HJ et al. The Lancet, May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8
Rojas J et al. “PCOS, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth.” Int J Reprod Med. 2014. PMC4334071
Moore AM et al. “Neuroendocrine mechanisms responsible for elevated GnRH and LH pulses in PCOS.” J Neuroendocrinol. 2025.
Rudnicka E et al. “Decoding androgen excess in PCOS.” World J Diabetes. 2025. PMC12278101
Shi Y, Zhao H. “Abnormal GnRH pulsatility in PCOS: recent insights.” Front Endocrinol. 2021. PMC7365617
Frontiers in Endocrinology: “Central Regulation of PCOS: Abnormal Neuronal-Reproductive-Metabolic Circuits.” 2021. PMC
Chen ZJ et al. “Progression of glucose intolerance and cardiometabolic risk factors over a decade in women with PCOS.” PLOS ONE. 2019. PMC6814217
Xu Y, Qiao J. “Association of Insulin Resistance and Elevated Androgen Levels with PCOS.” J Endocrinol Res. 2022. PMC8959968
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.